Captor Therapeutics Sa · GPW:CTX
Captor Therapeutics Sa — Investor Presentation (September 2022)
31 slides from Captor Therapeutics Sa's investor presentation, Sep 1, 2022
Slide 1: A new dawn in drug discovery
A new dawn in drug discovery Corporate Presentation 1 September 2022
Slide 2: Legal notice
Legal notice This document and the information contained herein (unless otherwise indicated) have been prepared by Captor Therapeutics S.A. (the “Issuer”) solely for informational purposes. For this notice, the presentation that follows shall mean and include the slides that follow, the oral present
Slide 3: Captor Therapeutics – key take-aways so far in 2022
Captor Therapeutics – key take-aways so far in 2022 OptigradeTM platform Key R&D Announcements Captor’s unique approach based ✓ CT-01: (chronological order) on Biophysics, Structural Biology • Compelling In vivo proof of concept data from in Hepatocellular Carcinoma and Chemistry are bearing fruit •
Slide 4: Agenda
Agenda • TEAM & STRATEGY • TARGETED PROTEIN DEGRADATION (TPD) • DEVELOPING BEST-IN CLASS AND FIRST-IN-CLASS DRUGS TO TREAT SEVERE DISEASES USING TPD TECHNOLOGY • FINANCIAL RESULTS • PLANS FOR THE FUTURE 4
Slide 5: Team & Strategy
Poa Captor * Therapeutics TEAM & STRATEGY
Slide 6: Vision – world-leading drug discovery & development using TPD
Vision – world-leading drug discovery & development using Targeted Protein Degradation (TPD) Wroclaw, Poland • Based in Wroclaw (Poland) and Basel (Switzerland) • Significantly oversubscribed IPO in April 2021 Basel, • Strong additional finance from non-dilutive funding Switzerland • Five drug progr
Slide 7: An experienced leadership team
An experienced leadership team LEADERSHIP TEAM Tom Shepherd, Ph.D. Michal Walczak, Ph.D. Radoslaw Krawczyk Sylvain Cottens, Ph.D. Chief Executive Officer Chief Scientific Officer Chief Financial Officer Co – founder – SVP Chemistry • Chief Executive Officer • Ph.D. ETH Zurich, • Chief Financial Offi
Slide 8: Three pillars of growth
Three pillars of growth The continued development of the platform provides Platform a continuous & sustainable flow of new drug projects development as pipeline drugs are commercialized Develop and commercialize Captor focuses on severe diseases where there drug are a lack of satisfactory treatments
Slide 9: TPD is one of the fastest growing areas of pharma research
2022 update TPD is one of the fastest growing areas of pharma research • The pharmaceutical market to reach $525 billion by 2025* • TPD is one of the fastest growing research fields • First generation TPD drugs are already on the market and sell billions of dollars (e.g., Revlimid) • Intense R&D spe
Slide 10: Poised to close the valuation gap vs peers
Poised to close the valuation gap vs peers Market Cap $132m* $370m $493m $740m $1,470m $2,250m Most advanced Pre-Clinical Pre-Clinical Phase 1 Phase 1 Phase 1 Phase 2 stage Oncology Oncology Oncology Oncology Oncology Focus Auto-inflammation Auto-inflammation Oncology Auto-inflammation Auto-inflamma
Slide 11: We maintain an active role in global TPD debate
We maintain an active role in global TPD debate 4TH ANNUAL Presentation: "Novel Molecular Dr Tom Shepherd, CEO invited to join expert TARGETED Glues in the Treatment of 8TH ANNUAL panel on Targeted Protein Degradation in this 2nd TPD PROTEIN Cancer", by Dr Michal Walczak, LSX WORLD London conference
Slide 12: Targeted Protein Degradation - a revolutionary approach
TARGETED PROTEIN DEGRADATION - A REVOLUTIONARY APPROACH 12
Slide 13: Principle of Targeted Protein Degradation
Principle of Targeted Protein Degradation 13 Business Use Only | Do not use without written consent of Captor Therapeutics Inc. © 2022 13
Slide 14: TPD: a revolutionary approach
TPD : a revolutionary approach “Traditional” inhibition or Targeted Protein Degradation occupancy based Drugs Strong interest from Benefits Benefits Pharma Companies with over + Highly specific due to targeting + 5x more druggable targets $31 BN in deal value to date1 + Fewer side effects compared t
Slide 15: Developing best-in class and first-in-class drugs using TPD technology
Developing best-in class and first-in-class drugs to treat severe diseases using TPD technology 15
Slide 16: Captor's Optigrade platform
Captor’s OptigradeTM platform Molecular Glues Platform differentiation Small molecules with good drug properties • Lead compounds both in molecular glues that stabilize the interaction between the E3 Ligase and the target Molecular and bifunctional degraders Glues • Structure-based hit finding and l
Slide 17: Company pipeline projects
Company pipeline projects # Indications Modality Discovery Preclinical* IND Filing FIH** FIH** Hepatocellular carcinoma CT-01 GSPT1, SALL4 + undisclosed MG target 2023/2024 Autoimmunity CT-02 MG Liquid tumors Liquid & solid tumours CT-03 BID MCL-1 CT-04 Colorectal cancer BID Autoimmunity CT-05 BID S
Slide 18: 2 drug candidates advancing towards the clinic
2 drug candidates advancing towards the clinic Project: Project: CT-01 CT-03 Molecular Positioning: Bifunctional Positioning: Glues Unique degradation profile Degraders First-in-class MCL-1 degrader Main indication: Main indications: hepatocellular carcinoma blood cancers • Anticancer activity in di
Slide 19: CT-01: oral efficacy in-vivo – strong tumor regression
CT-01: oral efficacy in-vivo – strong tumor regression Molecular Glue Human liver cancer model - Hep 3B2.1-7 (NSG mice) The study performed by reputable subcontractor Covance/LabCorp • CT-01 candidates induced tumour regression following oral administration (even at 10mg/kg orally) • Both compounds
Slide 20: CT-01: Addressing one of the deadliest cancers
CT-01: Addressing one of the deadliest cancers Molecular Glue • Hepatocellular Carcinoma (HCC) accounts for 75‐85% of primary liver cancers1 • ~ 700 000 new cases each year, the 2nd most common cause of cancer mortality1 • Rapidly growing due to link with liver & metabolic diseases • Curative treatm
Slide 21: CT-02: Broad Applicability of novel molecular glues
CT-02: Broad Applicability of novel molecular glues Project: CT-02 CNS (AZ) Molecular Main indication: Glues Autoimmunity, Oncology, CNS According to forecasts by the World Health Organization, the number of new leukemia cases worldwide will increase from about 437,000 in 2018 to about 603,000 in 20
Slide 22: CT-03: MCL-1 degrader in vivo efficacy results
CT-03: MCL-1 degrader in vivo efficacy results Bifunctional degraders CB.17/SCID mice xenografted s.c. with MV4-11 cells were administered CPT-2036 i.v. every three days (Q3D). Tumours were measured and animals were weighed twice per week. Mean Tumor Volume ± SEM Mean Tumor Volume ± SEM % Change Bod
Slide 23: MCL-1 – ultra high-value drug target
MCL-1 – ultra high-value drug target Bifunctional degraders • MCL-1 is a key mechanism in cancer cells’ resistance to drugs • Highly attractive target as it serves as a major pro-survival signal in: • Haematological malignancies (including Multiple Myeloma (MM), Acute Myeloid Leukaemia (AML), and no
Slide 24: Financial Results
Poa Captor * Therapeutics FINANCIAL RESULTS
Slide 25: Selected consolidated financial data
Selected consolidated financial data Revenues and financial results (PLN thousands) Consolidated statement of financial position (PLN, M) 130,6 124,2 H1 2022 H1 2021 111,4 108,1 Research and development income 2 227 1 454 Cost of services sold 585 - Net loss -20 840 - 12 801 13,0 16,4 9,6 11,4 Cash
Slide 26: Plans for the Future
Poa Captor * Therapeutics PLANS FOR THE FUTURE
Slide 27: Executive summary
Executive summary ▶ Major in-vivo efficacy milestones in CT-01, CT-03 ▶ Unique OptigradeTM platform based on Biophysics and structure guided design ▶ CT-02 makes breakthrough with potent degraders against an autoimmune target ▶ State of the art laboratory and continuous investment in new capabilitie
Slide 28: Near term objectives and milestones
Near term objectives and milestones WORKING TO DEVELOP PARTNERSHIPS WITH PLATFORM DRUG CANDIDATES OTHER ENTITIES DEVELOPMENT ▶ Announce additional in-vivo ▶ Execution of value creating ▶ Advancing our new ligase results in our pipeline projects contracts with further pharma ligands to develop a next
Slide 29: Q&A Session
Poa Captor * Therapeutics Q&A SESSION
Slide 30: Captor Therapeutics S.A contact details
Captor Therapeutics S.A ul. Duńska 11 54-427 Wrocław, Polska Captor Therapeutics GmbH Gewerbestrasse 24 4123 Allschwil, Szwajcaria IR Contact: Marta Święcicka m.swiecicka@captortherapeutics.com Media and IR Contact: captortherapeutics@pov.pl 30
Slide 31: Projects are co-financed by the European Regional Development Fund
Projects are co-financed by the European Regional Development Fund: Discovery and development of a new clinical drug candidate for the eradication of cancer stem cell in the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor (POIR.01.01.01-00-0740/19) Discov
Captor Therapeutics — Investor Presentation (September 2022) on 6ix